1. Home
  2. GIGM vs NXTC Comparison

GIGM vs NXTC Comparison

Compare GIGM & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GIGM

GigaMedia Limited

N/A

Current Price

$1.39

Market Cap

15.9M

Sector

Technology

ML Signal

N/A

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$4.40

Market Cap

17.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIGM
NXTC
Founded
1998
2015
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.9M
17.3M
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
GIGM
NXTC
Price
$1.39
$4.40
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
4.3K
3.3M
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$1.55
52 Week High
$1.89
$15.74

Technical Indicators

Market Signals
Indicator
GIGM
NXTC
Relative Strength Index (RSI) 45.98 48.92
Support Level $1.30 $4.01
Resistance Level $1.51 $10.66
Average True Range (ATR) 0.04 0.89
MACD -0.00 -0.03
Stochastic Oscillator 27.03 6.28

Price Performance

Historical Comparison
GIGM
NXTC

About GIGM GigaMedia Limited

GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: